Health Care Modeling For Forecasting Quality And Cost Outcomes Also Addresses Clinical Trial Needs
Archimedes, Inc.
, a San Francisco-based healthcare modeling company, and the
Robert Wood Johnson Foundation
announced that the US Department of Health and Human Services (HHS) has contracted with Archimedes to provide HHS agencies with direct access to the
ARCHeS Innovator
. The Archimedes Model, developed initially with support from Kaiser Permanente, is an advanced mathematical modeling tool available to answer complex questions on health and health care. Under this contract, HHS will make a new web-based interface called the Archimedes Healthcare Simulator (ARCHeS) available to its agencies, including the Centers for Medicare and Medicaid Services, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, the National Heart, Lung & Blood Institute and the Food & Drug Administration. For clinical trials, the modeling tool will users to run clinically realistic virtual trials on any population and to help with comparative effectiveness research, and clinical trial design and portfolio management.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
